Melagatran是一种通过防止人血小板-单核细胞异型复合物中组织因子表达而发挥作用的药物。研究表明，Melagatran在PRP血凝块模型中引起纤维蛋白溶解活性，这与在贫血的组织因子诱导的血凝块模型中观察到的结果相当。此外，这些研究还确定了Melagatran的纤维蛋白溶解能力不受血小板存在的影响。Melagatran以剂量依赖的方式影响血小板凝集，低浓度的血小板具有更大的功效。还已经提出，与α-凝血酶/ PAR-1受体相比，Melagatran可以差异地抑制γ-凝血酶/ PAR-4受体。 Melagatran is an agent which functions by preventing tissue factor expression in human platelet-monocyte heterotypic complexes. Studies indicate that Melagatran causes fibrinolytic activity in PRP clot models, which is comparable to that observed in platelet-poor models which consist of tissue factor-induced clots. In addition, these studies determined that the fibrinolysis ability of Melagatran is not affected by the presence of platelets. Melagatran effects platelet aggregation in a dose dependent manner, with low concentration having the greater effectiveness. Also it has been suggested that Melagatran can differentially inhibit γ-thrombin/PAR-4 receptors over α-thrombin/PAR-1 receptors.